학술논문
The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant
Document Type
Academic Journal
Author
Nasilowska-Adamska, B; Rzepecki, P; Manko, J; Czyz, A; Markiewicz, M; Federowicz, I; Tomaszewska, A; Piatkowska-Jakubas, B; Wrzesien-Kus, A; Bieniaszewska, M; Duda, D; Szydlo, R; Halaburda, K; Szczepinski, A; Lange, A; Hellman, A; Robak, T; Skotnicki, A; Jedrzejczak, W W; Walewski, J; Holowiecki, J; Komarnicki, M; Dmoszynska, A; Warzocha, K; Marianska, B
Source
Bone Marrow Transplantation. Nov 01, 2007 40(10):983-988
Subject
Language
English
ISSN
0268-3369
Abstract
In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 μg/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1-4 (58 vs 94%, P<0.001), 3-4 (13 vs 43%, P<0.001) and the median duration of OM (4 vs 9 days, P<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%, P<0.001), opioid analgesics (24 vs 64%, P<0.001) and total parenteral nutrition (11 vs 45%, P<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (P = 0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.